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We performed a retrospective case-series study of 
patients with inﬂ  uenza A (H5N1) admitted to the National 
Institute of Infectious and Tropical Diseases in Hanoi, Viet-
nam, from January 2004 through July 2005 with symptoms 
of acute respiratory tract infection, a history of high-risk 
exposure or chest radiographic ﬁ  ndings such as pneumo-
nia, and positive ﬁ   ndings for A/H5 viral RNA by reverse 
transcription–PCR. We investigated data from 29 patients 
(mean age 35.1 years) of whom 7 (24.1%) had died. Mor-
tality rates were 20% (5/25) and 50% (2/4) among patients 
treated with or without oseltamivir (p = 0.24), respectively, 
and were 33.3% (5/15) and 14.2% (2/14) among patients 
treated with and without methylprednisolone (p = 0.39), re-
spectively. After exact logistic regression analysis was ad-
justed for variation in severity, no signiﬁ  cant effectiveness 
for survival was observed among patients treated with osel-
tamivir or methylprednisolone.
H
uman infection with the highly pathogenic avian in-
ﬂ   uenza A virus (H5N1) was discovered in Hong 
Kong Special Administrative Region, People’s Repub-
lic of China, in 1997 (1–3). It has since been identiﬁ  ed in 
other countries, primarily in Southeast Asia. Among 100 
conﬁ  rmed infected patients, 46 have died in Vietnam since 
2003 (4,5).
Severe viral pneumonia accompanied by diffuse alve-
olar damage develops in patients infected with inﬂ  uenza vi-
rus (H5N1) (6). High viral load causes intense cytokine re-
actions and inﬂ  ammation (7). Clinical factors that might be 
associated with severity include age, delayed consultation, 
lower respiratory tract lesions, and leukopenia (4,8–10). 
However, few cases have reported which factors, including 
patient management, affect outcomes. Our study reviews 
the clinical courses of patients treated in Hanoi, Vietnam, 
and investigates the association between clinical ﬁ  ndings 
and survival.
The effects of oseltamivir and other neuraminidase 
inhibitors have been demonstrated in experimental mod-
els (11–13), but their outcomes in humans have not been 
veriﬁ  ed. Randomized controlled trials would be optimal 
for investigating the effectiveness of oseltamivir compared 
with placebo, but they are not an option because of ethical 
issues. Therefore, this issue can only be addressed through 
observational studies. Despite limited empirical evidence, 
the World Health Organization (WHO) reported that oselta-
mivir improved survival (14) and recommended treatment 
with oseltamivir because of high mortality rates associated 
with inﬂ  uenza A virus (14,15). Patients from northern Viet-
nam are described in detail.
Methods
We investigated patients infected with inﬂ  uenza A vi-
rus (H5N1) who were referred to the National Institute of 
Infectious and Tropical Diseases in Hanoi, Vietnam, from 
other local hospitals from January 2004 through July 2005. 
Pediatric patients were admitted to another institution in 
Hanoi and were excluded from the present study. A WHO 
inspection team at the National Institute for Hygiene and 
Epidemiology in Hanoi virologically conﬁ  rmed H5N1 sub-
type infection in the patients by using a reverse transcrip-
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tion–PCR (RT-PCR) for inﬂ  uenza A/H5. We investigated 
only patients with H5N1 subtype infection determined from 
symptoms of acute respiratory tract infection, a history of 
high-risk exposure, or chest radiographic ﬁ  ndings such as 
pneumonia. All patients were reported to WHO as having 
conﬁ  rmed infection with avian inﬂ  uenza virus (H5N1). We 
excluded other patients with positive RT-PCR results be-
cause of reasons described below. The study was reviewed 
and approved by the ethics committees at the International 
Medical Center of Japan and the National Institute of Infec-
tious and Tropical Diseases in Vietnam.
Data were obtained for general characteristics, history 
of high-risk exposure, medical history, symptoms, signs, 
microbiologic and biochemical test results, chest radio-
graphic ﬁ  ndings, treatment strategies, and outcomes from 
medical records from April through October 2006.
We investigated associations between clinical ﬁ  ndings 
and survival by using univariate analysis. Initial laboratory 
and chest radiographic ﬁ  ndings after hospitalization were 
recorded in the medical charts and used. The relationship 
between survival and treatment with oseltamivir or meth-
ylprednisolone was investigated by adjusting for factors 
related to severity in an exact logistic regression analysis, 
which is appropriate for small amounts or unbalanced bi-
nary data (16). Because the study cohort was small, deaths 
were few and overﬁ  tting was possible (17,18); only 1 cova-
riate could be added for adjustment into the logistic regres-
sion model. Therefore, we used leukocyte counts, platelet 
counts, aspartate aminotransferase (AST) levels, and urea 
nitrogen levels as an adjustment for severity because these 
values are associated with reported outcomes (14). Also, 
many missing observations prevented adjustment using al-
bumin levels. Data were analyzed by using the Wilcoxon 
test, χ2 test, and Fisher exact test when appropriate and the 
statistical package SAS version 8.2 (SAS Institute, Cary, 
NC, USA).
Results
Among 41 patients who were hospitalized from January 
2004 through July 2005 and had positive RT-PCR results, 
12 were excluded from the study (3 patients whose medical 
records were unavailable; 2 patients related to persons with 
conﬁ  rmed H5N1 subtype pneumonia who were asymptom-
atic, positive for viral RNA, and treated with prophylactic 
oseltamivir; and 7 patients who had some illnesses, particu-
larly respiratory diseases, which complicated interpretation 
of the clinical course or chest radiographic ﬁ  ndings). We 
therefore studied 29 patients with clinically and virologi-
cally conﬁ  rmed inﬂ  uenza A (H5N1) infection.
Table 1 shows the general characteristics of the pa-
tients, and the Figure shows the clinical course from on-
set of disease to hospitalization and discharge. Patients 
ranged in age from 14 to 67 years with a mean age of 
35.1 years. A total of 25 patients were given 150 mg/day 
of oseltamivir, and 15 were treated with methylpredni-
solone (initial dose 40–160 mg/day, median dose 80 mg/
day). Seven (24.1%) of the 29 patients died. No signiﬁ  cant 
associations were found between mortality rates and age 
(p = 0.57), sex (p = 0.68), history of high-risk exposure 
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Table 1. Characteristics of 29 patients infected with highly 
pathogenic avian influenza virus (H5N1), northern Vietnam, 
2004–2005*
Characteristic Value
Age, y, mean ± SD  35.1 ± 14.4 
M:F sex (%)  15:14 (52:48) 
High-risk exposure, no. (%)† 
Poultry 19 (65.5) 
Sick poultry  12 (41.4) 
Family infected with H5N1 virus subtype  6 (20.7) 
Sick poultry or person  15 (51.7) 
Hospitalization after disease onset, median, d 
(IQR) 
6 (4–8) 
Hospital stay, median, d (IQR)  14 (9–17) 
Treated with oseltamivir, no. (%)  25 (86.2) 
Began treatment with oseltamivir after disease 
onset, median, d (IQR) 
7 (5–10) 
Treated with methylprednisolone, no. (%)  15 (51.7) 
Died, no. (%)  7(24.1)
*IQR, interquartile range. 
†Poultry, a history of exposure to sick or healthy poultry; sick poultry or 
person, a history of exposure to sick poultry or a family infected with avian 
influenza (H5N1). 
Figure. Clinical course of 29 patients infected with highly pathogenic 
avian inﬂ  uenza virus (H5N1), northern Vietnam, 2004–2005. Zero 
days on horizontal axis represent days of hospitalization at the 
National Institute of Infectious and Tropical Diseases. Shaded bars, 
days between disease onset and hospitalization; open bars, days 
between hospitalization and discharge; dots, start of oseltamivir 
treatment. Information on the right shows date of hospitalization, 
age in years, sex, and leukocyte count per microliter.Human Infection with Avian Inﬂ  uenza Virus (H5N1)
(contact with poultry [p = 1.00], contact with sick poul-
try [p = 1.00], and contact with sick poultry or persons [p 
= 1.00]). Three of 6 patients from a family infected with 
H5N1 subtype died, and 4 of 23 patients without such an 
association died (p = 0.13). Duration between onset of dis-
ease and hospitalization was not associated with higher 
mortality rates (p = 0.98).
Table 2 shows initial laboratory ﬁ  ndings at hospital-
ization. Leukopenia (neutropenia), thrombocytopenia, hy-
poalbuminemia, and increased AST and urea nitrogen lev-
els were associated with increased deaths.
Five (20.0%) of the 25 patients treated with oseltamivir 
died, as did 2 (50.0%) of 4 who were not treated (odds ratio 
0.25, 95% conﬁ  dence interval [CI] 0.03–2.24, p = 0.24). 
To adjust for variation in disease severity among patients, 
exact logistic regression was performed by using leukocyte 
counts, platelet counts, AST levels, and urea nitrogen lev-
els. Adjusted odds ratios for deaths among patients treated 
with oseltamivir were 0.15 (95% CI 0.00–2.57, p = 0.19), 
0.16 (95% CI 0.00–2.23, p = 0.17), 0.54 (95% CI 0.02–
11.85, p = 1.00), and 0.28 (95% CI 0.01–5.16, p = 0.55), 
respectively, for the 4 adjustments for disease severity.
The time between the onset of symptoms and initia-
tion of treatment with oseltamivir varied (Table 1, Figure). 
The mortality rates were 20% (3/15) and 20% (2/10) when 
treatment with oseltamivir was started within and after 7 
days of disease onset.
Methylprednisolone was given to 15 of 29 patients. 
Five (33.3%) of these 15 patients died, and 2 (14.3%) of 
14 patients who were not given this drug died (odds ra-
tio 3.0, 95% CI 0.48–18.93, p = 0.39). Exact logistic re-
gression after adjustment for severity by using leukocyte 
counts, platelet counts, AST levels, or urea nitrogen levels 
showed odds ratios for deaths among patients treated with 
methylprednisolone of 0.74 (95% CI 0.00–9.57, p = 0.82), 
1.82 (95% CI 0.18–25.48, p = 0.89), 1.14 (95% CI 0.07–
18.92, p = 1.00), and 2.43 (95% CI 0.28–31.69, p = 0.61), 
respectively.
Thirteen patients were treated with oseltamivir and 
methylprednisolone. The regression model that included 
these 2 drugs and interactions did not show effectiveness 
of either drug.
Discussion
The overall mortality rate of 24.1% in this study was 
lower than rates in previous studies and WHO reports. 
Table 3 summarizes the characteristics of patients from 
previous studies. Patients in the present study were older 
because pediatric patients were excluded because of treat-
ment elsewhere. WHO has reported that the mortality rate of 
73% for infection with H5NI subtype is highest in persons 
10–19 years of age, and that patients 20–39 years of age ac-
count for >60% of the deaths (22). The expected mortality 
rate would be 51.8% if our case-patients had the same age-
speciﬁ  c mortality rate as in a WHO report (14). The lower 
mortality rate in our study could not be explained by an age 
difference. The relatively high leukocyte count and factors 
related to outcomes suggest that a reasonably large num-
ber of mildly infected patients might have been included, 
although chest radiographs showed variable progression in 
lesions from mild to severe.
Persons who died were concentrated in the early pe-
riod of the study, especially in 2004. Virus genotype and 
load data could provide useful information on pathogenesis 
and outcome. However, these data were not available.
Factors affecting outcome were leukocyte and plate-
let counts, and albumin, ALT, and urea nitrogen levels. 
Results were consistent with previous ﬁ  ndings (14) and 
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Table 2. Initial laboratory and chest radiographic results for 29 patients infected with highly pathogenic avian influenza virus (H5N1), 
northern Vietnam, 2004–2005* 
Characteristic
Survived, median (interquartile range), 
n = 22
Died, median (interquartile range), 
n = 7 p value
Leukocytes, × 10
3/PL 7.8 (7.1–12.0) 3.4 (1.7–5.6)† 0.0093
Neutrophils, ×10
3/PL 6.8 (4.8–9.9) 2.3 (1.1–3.8)† 0.0101
Hemoglobin, g/L 130 (107–137) 121 (103–138) 0.6102
Platelets, × 10
3/PL 214 (181–284) 86 (38–139)† 0.0101
Albumin, g/L 34.5 (31.2–35.1) 21.7 (10.4–29.4)† 0.0265
AST, U/L 45 (28–69) 327 (77–352)† 0.0077
Total bilirubin, Pmol/L 10.3 (7.6–16.8) 11.4 (7.0–27.1) 0.7921
Urea nitrogen, mmol/L 4.5 (3.4–5.5) 9 (3.4–14.3)† 0.0462
Initial chest radiographic findings‡
  No or slight lesion 7 1 0.6510
 Moderate  lesion 10 3
 Severe  lesion 53
*Not all laboratory findings and chest radiographic results were available. Results were derived from the following numbers of patients: complete blood 
count, 29; albumin 12; AST, 25; total bilirubin, 17; urea nitrogen, 27. AST, aspartate aminotransferase. 
†p<0.05, by Wilcoxon test or Fisher exact test. 
‡No or slight lesion, no lesion or localized (occupying less than one third of unilateral lung fields) in 1 lung; moderate, diffuse in 1 lung or localized but 
evident in both lungs; severe, diffuse in both lungs. RESEARCH
suggested that outcome is related to lesions in several 
organs.
Although the mortality rate was lower among patients 
treated with oseltamivir, differences were not signiﬁ  cant. 
Exact logistic regression after adjustments for laboratory 
results yielded an odds ratio of 0.15–0.54 for death. The 
small number of patients prevented valid adjustment, and 
confounding factors might not have been sufﬁ  ciently elimi-
nated. A larger patient cohort should be able to adjust for 
severity of disease.
If one considers the possibility of confounding fac-
tors, the reason oseltamivir was not prescribed should be 
investigated. If oseltamivir was withheld from patients 
with severe infections and administered only to those with 
milder symptoms, the drug would apparently be more ef-
fective. Among 4 patients who were not prescribed oselta-
mivir, initial RT-PCR results were negative for 1 patient, 
who subsequently died. Oseltamivir was unavailable for 
treatment of another patient who died. The other 2 surviv-
ing patients were not prescribed oseltamivir because their 
chest radiographs showed only minimal lesions. There-
fore, withholding oseltamivir was not associated with 
disease severity.
Higher doses of oseltamivir or longer drug adminis-
tration have improved outcomes in animal models (23,24). 
Because all patients in our study were given oseltamivir at 
a dose of 150 mg/day, we could not investigate the effect 
of a higher dose.
Mortality rates were higher in patients treated with 
methylprednisolone than in those not treated with this drug. 
This ﬁ  nding can be explained by disease severity because 
severely ill patients were more likely to be given methyl-
prednisolone. However, even after we adjusted for this con-
founding effect, no beneﬁ  cial effect of methylprednisolone 
was observed. Further, an experimental model has recently 
raised doubt about the effect of cytokine suppression (25).
Our study described patients infected with inﬂ  uenza A 
virus (H5N1) in Hanoi, Vietnam. These patients had lower 
mortality rates than those reported in other studies. The 
reason for the low mortality rate could not be investigated 
thoroughly without virologic information. Oseltamivir was 
prescribed in 25 of 29 patients, and their mortality rate was 
apparently decreased, although the patient cohort was too 
small to generate sufﬁ  cient statistical power. In addition, 
since our study was an observational study, these ﬁ  ndings 
might have been inﬂ  uenced by confounding factors. Fur-
ther detailed observations from a larger number of patients 
are required. 
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